Visceral Heterotaxy 8 (HTX8) — Comprehensive Disease Characteristics Report

Disease: Visceral Heterotaxy 8 (HTX8) · MONDO: MONDO:0014967 · Gene: PKD1L1 · Category: Mendelian (autosomal recessive) Report date: 2026-10-20 · Evidence base: human clinical case reports, model-organism genetics, in-vitro/biochemical, and computational/database sources.

Summary answer. Visceral Heterotaxy 8 (HTX8; OMIM #617205) is a rare autosomal-recessive laterality (left–right patterning) disorder caused by biallelic loss-of-function or damaging variants in PKD1L1 (polycystin-1-like 1, chr 7p12.3). PKD1L1 partners with PKD2 (polycystin-2/TRPP2) on motile cilia of the embryonic node/Kupffer's vesicle to sense leftward "nodal flow"; its loss disrupts the earliest left-biased Ca²⁺/Nodal signal, randomizing or bilateralizing organ situs and producing a spectrum from situs inversus totalis to situs ambiguus (heterotaxy) with frequent complex congenital heart disease and splenic anomalies (including asplenia). There is no gene-specific therapy; management is anatomy-driven (cardiac surgery, infection prophylaxis for asplenia), and prognosis is governed mainly by the severity of congenital heart disease.

1. Disease Information

Overview. HTX8 is a Mendelian subtype of visceral heterotaxy — a congenital disorder of left–right (L-R) body-axis determination in which thoracic and abdominal organs are abnormally arranged across the midline. Clinically it ranges from situs inversus totalis (SIT) (complete mirror-image reversal) to situs ambiguus / heterotaxy (discordant, randomized organ positioning), typically with congenital heart disease (CHD). "Disruption of the establishment of left-right (L-R) asymmetry leads to situs anomalies ranging from situs inversus totalis (SIT) to situs ambiguus (heterotaxy)" (27616478).

Key identifiers. - MONDO: MONDO:0014967 (Visceral heterotaxy 8) - OMIM: #617205 (phenotype, HTX8, autosomal recessive); gene PKD1L1 *609721 - Gene/HGNC: PKD1L1, HGNC:18053; Ensembl ENSG00000158683; NCBI Gene 168507; UniProt Q8TDX9 - Orphanet: broad entry ORPHA:450 (Heterotaxia); no PKD1L1-specific ORPHA code - MeSH: D059446 (Heterotaxy Syndrome) - ICD-10: Q89.3 (Situs inversus); ICD-11: LB01.1 (Situs ambiguous / heterotaxy) - HPO anchor: HP:0004935 (Visceral heterotaxy)

Synonyms / alternative names. Heterotaxy, visceral, 8, autosomal recessive; HTX8; PKD1L1-related heterotaxy/laterality defect; situs ambiguus/situs inversus due to PKD1L1.

Information source type. Derived from aggregated disease-level resources (OMIM, Orphanet, ClinVar, UniProt, gnomAD) combined with individual patient case reports (small families); not from large EHR cohorts.

2. Etiology

Primary cause — genetic. Biallelic (homozygous or compound-heterozygous) pathogenic variants in PKD1L1. Whole-exome sequencing "identified homozygous mutations in PKD1L1 from three affected individuals in two unrelated families" (27616478). This is a monogenic, recessive developmental disorder; it is not infectious and has no established acquired cause.

Genetic risk factors. - Causal variants: loss-of-function (splice, nonsense) and damaging missense alleles in PKD1L1 (see §4). - Consanguinity is a key risk context — reported probands are homozygous, consistent with autosomal-recessive inheritance and increased in consanguineous or founder settings. - Carrier status: heterozygotes are unaffected (gene is not haploinsufficient; gnomAD pLI≈0).

Environmental risk factors. None established specifically for HTX8. For heterotaxy broadly, maternal pregestational diabetes mellitus is associated with laterality/abdominal-situs phenotypes (41974186) and is a recognized teratogenic risk factor for L-R defects; this is a disease-level association, not demonstrated for PKD1L1 cases.

Protective factors. None identified (genetic or environmental). A single wild-type PKD1L1 allele is "protective" in the Mendelian sense (carriers are healthy).

Gene–environment interactions. Not specifically characterized for PKD1L1. Laterality determination is a threshold/stochastic developmental process; modifier/background effects are plausible (variable expressivity between SIT and heterotaxy even within families) but unproven.

3. Phenotypes

All manifestations are congenital (prenatal/neonatal onset), structural/physical, lifelong, and non-progressive as malformations (clinical course is driven by complications). Frequencies below are qualitative given the very small reported cohort.

Onset: neonatal/congenital (often detected prenatally). Severity: variable — from isolated SIT (potentially mild) to lethal complex CHD. Progression: stable malformation; secondary deterioration from cardiac failure, arrhythmia, or infection. Quality of life: dominated by cardiac disease burden (surgeries, heart failure, arrhythmia) and, in asplenia, lifelong infection vigilance; no disease-specific QoL instruments exist — generic pediatric CHD tools (PedsQL, PROMIS) apply.

4. Genetic / Molecular Information

Causal gene. PKD1L1 (polycystin-1-like 1), HGNC:18053, Ensembl ENSG00000158683, gene OMIM *609721, GRCh38 chr7:47,740,202–47,948,466 (7p12.3), canonical transcript ENST00000289672; protein UniProt Q8TDX9, 2849 aa.

Protein architecture (UniProt Q8TDX9). 11-transmembrane polycystin-1-family receptor with a large extracellular N-terminus (res. 1–1748): two PKD domains (508–590; 592–673), a large REJ (receptor-for-egg-jelly) domain (674–1571), a GAIN-B domain (1587–1735) containing the GPS autoproteolysis motif (1691–1735), and a cytoplasmic PLAT/LH2 domain (1796–1913); ~20 N-glycosylation sites and disulfide bonding.

Reported pathogenic variants (germline). | Variant (cDNA) | Protein | Class | Consequence | Phenotype | PMID | |---|---|---|---|---|---| | c.6473+2_6473+3delTG | splice-donor, intron 42 | Splice-site, LoF | Loss of function | Heterotaxy + complex CHD | 27616478 | | c.5072G>C | p.Cys1691Ser | Missense (GPS motif) | Disrupts GPS disulfide, folding/autoproteolysis | SIT + CHD | 27616478 | | c.1387C>T | p.Gln463* | Nonsense, LoF | Truncation (loss of REJ/TM/channel region) | Heterotaxy + congenital asplenia | 35691949 |

"the p.Cys1691Ser substitution affects a highly conserved cysteine residue and is predicted by molecular modeling to disrupt a disulfide bridge essential for the proper folding of the … (GPS) motif" (27616478).

Variant classification & frequency. ClinVar lists ~1,417 PKD1L1 variants, the large majority variants of uncertain significance (VUS) (~1,157 VUS vs ~170 pathogenic / ~72 likely pathogenic), reflecting limited functional/segregation data. Pathogenic HTX8 alleles are individually rare/absent in population databases (gnomAD). Origin: germline. Functional consequence: loss of function (recessive); no gain-of-function or dominant-negative mechanism established.

Population constraint (gnomAD). pLI ≈ 0, oe_lof = 0.73 (90% CI 0.66–0.81), missense oe = 0.95, mis_z = 1.35. The gene is not haploinsufficient, consistent with asymptomatic heterozygous carriers and recessive disease.

Modifier genes. None proven. Variable expressivity (SIT vs heterotaxy) suggests modifiers/stochastic effects. In mouse genetics, Pkd1l1 acts as an upstream repressor of Pkd2 (27272319), so dosage of polycystin-pathway genes is biologically relevant.

Epigenetics / chromosomal abnormalities. No HTX8-specific epigenetic signature reported. HTX8 is caused by point/small variants, not large chromosomal rearrangements; however, CNVs in body-patterning pathways (NODAL/BMP/WNT, e.g., NIPBL, TBX6, FGF12, RBFOX1) contribute to the broader heterotaxy population (27637763).

5. Environmental Information

• Environmental factors / toxins / infectious agents: none causal for HTX8 (purely genetic).
• Lifestyle factors: not applicable to disease causation.
• Disease-level association: maternal pregestational diabetes correlates with laterality-spectrum phenotypes (41974186) — relevant to heterotaxy broadly, not to monogenic PKD1L1 cases.
• Infectious agents: not causal, but secondary infection risk is central in patients with asplenia (see §11/§13).

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. Biallelic PKD1L1 loss-of-function/damaging variant → results in absent or misfolded PKD1L1 protein (truncation; GPS-motif disulfide disruption for p.Cys1691Ser). [demonstrated: human genetics + molecular modeling]
2. Loss of functional PKD1L1 → prevents assembly of the PKD1L1–PKD2 (polycystin-1-like-1 / polycystin-2) receptor–channel complex on cilia of the embryonic node / Kupffer's vesicle. [demonstrated: co-localization + physical interaction, mouse & medaka]
3. Motile node cilia still generate normal leftward "nodal flow" (cilia motility is intact) → but the flow cannot be interpreted without the PKD1L1–PKD2 sensor. [demonstrated: normal flow/cilia in mutants]
4. Flow normally transfers PKD1L1-containing fibrous strands leftward, facilitating a left-dominant intracellular Ca²⁺ elevation at the left node margin (FGFR/Shh-dependent) → in mutants this earliest left-biased signal fails. [demonstrated in mouse; Tanaka 2023]
5. Failed/symmetric Ca²⁺ signaling → loss of left-restricted repression such that the Nodal–Lefty–Pitx2 cascade is not confined to the left (becomes absent, bilateral, or randomized) in the lateral plate mesoderm. [demonstrated: PKD1L1 restricts Nodal to the left; Pkd1l1 mutant activates Nodal bilaterally]
6. Loss of asymmetric Pitx2 patterning → randomized/discordant morphogenesis and looping of heart, gut, spleen, lungs and great vessels. [inferred from conserved L-R pathway]
7. Abnormal situs → situs inversus totalis OR situs ambiguus/heterotaxy with complex CHD, splenic anomalies, intestinal malrotation, vascular laterality defects → clinical disease. [demonstrated: human phenotypes]

Branch point at step 5: depending on whether Nodal is lost, bilateral, or randomized, the organism develops SIT (coordinated reversal), left isomerism (polysplenia), or right isomerism (asplenia) — explaining the phenotypic spectrum, including the asplenia case (35691949).

Supporting detail by category. - Molecular pathways: Nodal/TGF-β signaling (Nodal–Lefty2–Pitx2), upstream FGFR and Sonic hedgehog (Shh) signaling, calcium signaling. Reactome "Nodal signaling"; KEGG TGF-β pathway. - Protein dysfunction: loss of function via truncation or GPS-domain misfolding; PKD1L1 normally undergoes GPS autoproteolysis and forms a Ca²⁺-permeable channel complex with PKD2/TRPP2. "PKD1L1 is sufficient to mediate a Ca2+ signaling response after flow stimulation … an extracellular PKD domain within PKD1L1 is crucial for PKD1L1 function" (27272319). - Cellular processes: ciliary mechanosensation/chemosensation and ciliary Ca²⁺ signaling; embryonic L-R symmetry breaking. - Biochemical abnormality: defective ciliary cation (Ca²⁺) channel/receptor complex. - Immune involvement: not primary; functional/anatomic asplenia causes secondary immunodeficiency to encapsulated bacteria. - Metabolic/epigenetic changes: none characteristic.

GO term suggestions: GO:0007368 (determination of left/right symmetry); GO:0003351 (epithelial cilium movement involved in determination of L/R asymmetry); GO:0060287 (epithelial cilium / "nodal cilium"); GO:0060170 (ciliary membrane); GO:0005929 (cilium); GO:0072372 (primary cilium assembly); GO:0005262 (calcium channel activity); GO:0019228/GO:0070588 (Ca²⁺ ion transmembrane transport). Cell Ontology (CL): node/pit cells & crown cells of the embryonic organizer → CL:0000222 (mesodermal cell), ciliated embryonic node cells; CL:0000057 (fibroblast, LPM context). CHEBI: CHEBI:29108 (calcium(2+)).

7. Anatomical Structures Affected

Organ level (primary): heart and great vessels (cardiovascular), spleen (asplenia/polysplenia), stomach/intestine (malrotation), liver (midline/abnormal lobation), lungs (isomerism), inferior vena cava/systemic veins. Body systems: cardiovascular (primary), digestive, respiratory, lymphatic/immune (spleen), hepatobiliary. Secondary involvement: immune deficiency from asplenia; biliary atresia in some left-isomerism heterotaxy; pulmonary consequences of CHD.

Developmental origin (where the defect acts): the embryonic node / Kupffer's vesicle (midline left–right organizer) and lateral plate mesoderm — UBERON:0005725 (ciliated embryonic node) / UBERON:0004341 (node), UBERON:0003081 (lateral plate mesoderm). Resulting organ UBERON terms: UBERON:0000948 (heart), UBERON:0002106 (spleen), UBERON:0000160 (intestine), UBERON:0002048 (lung), UBERON:0001072 (inferior vena cava).

Tissue/cell level: ciliated epithelial cells of the node/KV; lateral-plate mesoderm; cardiac progenitor mesoderm. Subcellular (GO Cellular Component): primary/motile cilium (GO:0005929), ciliary membrane (GO:0060170), plasma membrane.

Localization & lateralization: defect is of body-axis laterality itself — manifestations are intrinsically bilateral/asymmetric/randomized (loss of normal left-right asymmetry; isomerism = loss of sidedness). HPO HP:0001631 etc. for specific cardiac lesions.

8. Temporal Development

• Onset: congenital; organ situs is specified in early embryogenesis (gastrulation/node stage, ~weeks 3–4 in humans). Frequently diagnosed prenatally by ultrasound/fetal echocardiography (heterotaxy has among the highest prenatal detection rates, ~91% in one series, 42324491).
• Onset pattern: structural malformation present at birth (not acute/subacute).
• Progression: the malformation is stable; clinical course is non-progressive as a lesion but complicated by heart failure, arrhythmia (complete heart block), pulmonary venous obstruction, and infection.
• Critical period: the node/LPM signaling window in early embryogenesis is the only period during which L-R situs can be set — there is no postnatal window to correct the primary patterning defect, only to palliate its consequences.
• Duration: lifelong (chronic).

9. Inheritance and Population

• Inheritance: autosomal recessive (biallelic PKD1L1). Heterozygous carriers unaffected.
• Penetrance/expressivity: biallelic genotypes appear highly penetrant for a laterality phenotype, but expressivity is variable (SIT vs heterotaxy; differing CHD severity, including within the same family).
• Consanguinity: relevant — reported probands are homozygous; recessive disease risk rises with consanguinity/founder effects.
• Carrier frequency / founder effects: not precisely established; individual pathogenic alleles are rare; a Chinese nonsense allele (p.Gln463*) was the first reported in that population (35691949).
• Anticipation / mitochondrial / germline mosaicism: not applicable / not reported.

Epidemiology. - HTX8 specifically: ultra-rare; only a handful of families reported worldwide — population prevalence unknown. - Heterotaxy / atrial isomerism (parent category): prevalence ~1 in 10,000–20,000 live births, accounting for up to ~4% of all cardiac malformations (34491249); heterotaxy represents a minority of laterality disorders (e.g., 249 HS among 566 fetal laterality cases over 721,562 deliveries, 42110452). - Sex ratio / geography: no established PKD1L1-specific skew; general heterotaxy shows modest male predominance in some registries. Reported PKD1L1 cases span diverse ancestries (consistent with private recessive alleles).

10. Diagnostics

Imaging (anatomic diagnosis, primary). - Fetal ultrasound + fetal echocardiography — mainstay prenatal detection (very high detection for heterotaxy, 42324491). - Postnatal echocardiography, cardiac CT/MRI/angiography for segmental cardiac/vascular anatomy; abdominal ultrasound/CT for spleen, liver, gut malrotation; upper GI series for malrotation. Laboratory / functional. - Peripheral blood smear for Howell-Jolly bodies → screen for functional asplenia; pitted-RBC counts / spleen scintigraphy to assess splenic function. - ECG/Holter for complete heart block and arrhythmia.

Genetic testing (definitive molecular diagnosis). - Approach: because heterotaxy is highly heterogeneous ("pathogenic genetic lesions are found in less than 20% of HS patients," 35691949), broad testing is preferred: multigene heterotaxy/CHD panels (including PKD1L1, ZIC3, NODAL, CFC1, ACVR2B, LEFTY2, GDF1, MMP21, CCDC11/CFAP53, DNAH5…), whole-exome (WES) or whole-genome sequencing (WGS). WES identified the original PKD1L1 families (27616478). - Single-gene testing of PKD1L1 is appropriate when a consistent phenotype or family variant is known; confirm biallelic status and parental phase (segregation). - Chromosomal microarray (CMA)/karyotype to exclude CNVs/aneuploidy contributing to heterotaxy (27637763). - Interpretation caveat: high VUS burden in PKD1L1 — classification benefits from recessive segregation, consanguinity, GPS/LoF functional rationale, and ACMG/AMP criteria.

Clinical criteria / differential diagnosis. No disease-specific criteria; diagnosis = demonstrated situs anomaly + biallelic PKD1L1 variants. Differential: other genetic heterotaxy (X-linked ZIC3 = HTX1; NODAL, CFC1, ACVR2B, GDF1, MMP21, etc.), primary ciliary dyskinesia (PCD) with laterality defects (distinguished by chronic sinopulmonary disease, abnormal ciliary motility/ultrastructure, nasal nitric oxide — features absent in PKD1L1, whose cilia are motile), and syndromic/CNV causes.

Screening. No newborn screening for HTX8; cascade carrier testing of relatives and prenatal/preimplantation genetic testing are options once the familial variants are known.

11. Outcome / Prognosis

• Prognosis is driven by the cardiac phenotype. In a heterotaxy+CHD cohort (n=197), 5- and 10-year survival ≈71% and ≈68%; left atrial isomerism had better survival than right atrial isomerism; complete heart block (CHB) and ventricular dysfunction predicted fetal demise, and pulmonary venous obstruction + CHB predicted postnatal mortality (42185088). "CHB and pulmonary venous obstruction remain significant predictors of postnatal mortality…" (42185088).
• Infection/asplenia mortality: asplenia confers high risk of overwhelming bacteremia — in a systematic review, "There were 42 documented cases of bacteremia in 32 patients. Approximately, 79% of these had absence of a spleen" (27425254), mean age ~17 months, with high mortality.
• Perinatal outcomes (laterality spectrum): major CHD drives termination, surgery and early mortality; live birth ~80%, with infant mortality concentrated in infancy (41974186).
• Morbidity: multiple cardiac surgeries, arrhythmia/pacemaker dependence, heart failure, GI morbidity (malrotation/volvulus), feeding/growth problems; lifelong infection risk with asplenia.
• Prognostic factors: type/severity of CHD, atrial isomerism subtype (RAI worse), CHB, pulmonary venous obstruction, splenic status. No molecular prognostic biomarker specific to PKD1L1.

12. Treatment

No disease-specific or gene-directed therapy exists. Management is symptomatic, anatomy-driven, and multidisciplinary (NCIT terms suggested). - Cardiac surgical/interventional: staged palliation (single-ventricle pathway: Norwood/Glenn/Fontan) or biventricular repair depending on anatomy; repair of AVSD, TAPVC, DORV; pacemaker for complete heart block (NCIT: C157809 Cardiac Surgery; C50106 Pacemaker; C98298 Fontan Procedure). - Gastrointestinal: Ladd procedure for intestinal malrotation/volvulus (NCIT: C157751 surgical procedure). - Asplenia management (critical): vaccination against encapsulated organisms — pneumococcal (PCV + PPSV23), Haemophilus influenzae type b, meningococcal (ACWY + B) — plus antibiotic prophylaxis (e.g., penicillin/amoxicillin) and immediate empiric antibiotics for febrile illness (NCIT: C15346 Vaccination; C154547 Antibiotic Therapy; C15431 Prophylaxis). Patient education and medical-alert measures improve adherence (32759171; 31937251). - Supportive: heart-failure pharmacotherapy (diuretics e.g. furosemide, afterload reduction, beta-blockade), nutritional support/gastrostomy, arrhythmia management (41049903 case series). - Advanced/experimental therapeutics: none — no gene therapy, RNA therapy, cell therapy, or targeted/immunotherapy for PKD1L1-heterotaxy (the primary defect is prenatal/developmental and not correctable postnatally). No pharmacogenomic considerations specific to the gene. - Pharmacogenomics / personalized medicine: genotype confirms diagnosis and informs recurrence risk/reproductive counseling rather than drug selection.

13. Prevention

• Primary prevention: not possible for the genetic lesion. Preconception/prenatal genetic counseling for recessive 25% recurrence risk; carrier screening of partners in known families; PGT/prenatal diagnosis where familial variants are defined. Optimizing maternal glycemic control addresses a disease-level (not PKD1L1-specific) laterality risk factor (41974186).
• Secondary prevention: prenatal detection (fetal echo/ultrasound) enabling planned delivery at a cardiac center and early intervention (42324491); early postnatal spleen-function assessment (Howell-Jolly bodies).
• Tertiary prevention (prevent complications): the cornerstone — asplenia vaccination + antibiotic prophylaxis to prevent overwhelming post-splenectomy/asplenia sepsis (27425254; 31937251; 32759171); arrhythmia surveillance/pacing; surgical correction of malrotation before volvulus; endocarditis prophylaxis per cardiac guidelines.
• Genetic counseling: autosomal-recessive counseling; cascade testing; reproductive options.

14. Other Species / Natural Disease

• Conservation: PKD1L1's L-R role is highly conserved across vertebrates. Orthologs: mouse Pkd1l1 (NCBI Gene 207225; MGI), medaka pkd1l1 (ZFIN/medaka; the classic L-R mutant abecobe/abc), zebrafish pkd1l1 (ZFIN). Taxa: Mus musculus (NCBI:txid10090), Oryzias latipes (medaka, NCBI:txid8090), Danio rerio (NCBI:txid7955).
• Natural animal disease / veterinary: no well-characterized naturally occurring PKD1L1 heterotaxy disease in companion animals is documented in OMIA for this gene; situs/laterality anomalies occur sporadically across species but are not established as a PKD1L1 natural disease.
• Comparative biology: mouse and fish models reproduce the human mechanism (node/KV flow-sensing), making them the key translational systems (see §15). Evolutionary note: the two-cilia/polycystin flow-sensing paradigm is conserved from fish to mammals.
• Zoonotic potential: not applicable (non-infectious developmental disorder).

15. Model Organisms

Mouse (Mus musculus) — primary mammalian model. - Types: Pkd1l1 knockout (e.g., gene-trap/null line, Vogel 2010, 20080492) and ENU/point mutants (e.g., rks); knock-in reporter KikGR-PKD1L1 for live protein imaging (Tanaka 2023, 37413993). - Phenotype recapitulation (strong): situs inversus/laterality defects; "both mutants fail to activate asymmetric gene expression at the node or in the lateral plate and exhibit right isomerism of the lungs" (21307093). Node morphology and cilia motility normal → defect is in flow interpretation, matching human mechanism. - Key insight: "the absence of respiratory tract lesions, hydrocephalus, and male infertility in Pkd1l1(-/-) mice … suggested that dysfunction of motile cilia was not involved" (20080492) — distinguishes HTX8 from PCD. - Limitation: high perinatal lethality of nulls; models the developmental patterning defect but not the postnatal human CHD surgical course.

Medaka (Oryzias latipes). The L-R mutant abecobe (abc) = pkd1l1: "abecobe (abc) is defective for left-right asymmetric expression of southpaw, lefty and charon, but not for nodal flow" (21307098); PKD1L1 required in Kupffer's vesicle and colocalizes/interacts with Pkd2 on motile KV cilia.

Zebrafish (Danio rerio). pkd1l1 expressed in KV; morpholino/mutant studies implicate polycystin signaling in L-R patterning (Kupffer's vesicle = node equivalent).

In-vitro / cellular. Cultured cells supplied artificial flow show PKD1L1 is "sufficient to mediate a Ca2+ signaling response after flow stimulation" (27272319); heterologous PKD1L1–PKD2 complexes used for biochemistry/channel studies.

Applications: dissecting node/KV flow sensing, polycystin complex assembly, Nodal cascade restriction, Ca²⁺ signaling, and variant functional testing. Resources: MGI, IMPC, ZFIN, Alliance of Genome Resources.

Supported vs. Refuted Hypotheses

Supported. 1. HTX8 is autosomal-recessive, caused by biallelic PKD1L1 LoF/damaging variants (27616478 35691949). 2. PKD1L1–PKD2 ciliary complex is the nodal-flow sensor restricting Nodal to the left (21307093 21307098 27272319 37413993). 3. The pathology is a flow-interpretation (sensory) defect, not a ciliary-motility defect → mechanistically distinct from PCD (20080492). 4. Prognosis is governed by CHD severity and asplenia-related infection risk (42185088 27425254).

Refuted / not supported. - PKD1L1 is not a dominant/haploinsufficient disease gene (gnomAD pLI≈0; carriers healthy). - HTX8 is not driven by motile-cilia dysfunction (no PCD airway/hydrocephalus phenotype in nulls). - No evidence for gain-of-function, somatic, infectious, or acquired/environmental primary causation.

Limitations and Future Directions

• Very small human evidence base (few families); PKD1L1-specific prevalence, penetrance, sex ratio, and natural history are not quantified — most clinical figures derive from the broader heterotaxy category.
• High VUS burden limits molecular diagnosis; functional assays (flow-induced Ca²⁺, GPS autoproteolysis, PKD1L1–PKD2 trafficking) are needed to reclassify variants.
• No structural model of the human PKD1L1–PKD2 complex at the variant level; cryo-EM would clarify GPS/PKD-domain variant effects.
• No targeted therapy; research should define modifier genes, improve prenatal risk stratification, and standardize asplenia prophylaxis in this population.

Key references (PMIDs)

27616478 (Vetrini 2016, human biallelic PKD1L1); 35691949 (Gu 2022, nonsense + asplenia); 21307093 (Field 2011, mouse); 21307098 (Kamura 2011, medaka); 27272319 (Grimes 2016, epistasis/Ca²⁺); 37413993 (Tanaka 2023, flow transfers polycystin); 20080492 (Vogel 2010, Pkd1l1−/− mouse); 24756726 (TRPP/polycystin review); 42185088 (heterotaxy+CHD outcomes); 27425254 (bacteremia in heterotaxy); 34491249 (isomerism epidemiology); 42324491 (prenatal detection); 41974186 (laterality spectrum outcomes/PDM); 27637763 (heterotaxy CNVs); 38884744 (human genetics of situs); 32759171 / 31937251 (asplenia prophylaxis).